HomeCompareADYX vs RYLD

ADYX vs RYLD: Dividend Comparison 2026

ADYX yields 2000000.00% · RYLD yields 12.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADYX wins by $1.6247481716182984e+23M in total portfolio value
10 years
ADYX
ADYX
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.6247481716182984e+23M
Annual income
$147,608,011,402,949,780,000,000,000,000.00
Full ADYX calculator →
RYLD
RYLD
● Live price
12.14%
Share price
$14.95
Annual div
$1.81
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.5K
Annual income
$2,587.35
Full RYLD calculator →

Portfolio growth — ADYX vs RYLD

📍 ADYX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodADYXRYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ADYX + RYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ADYX pays
RYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADYX
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$125,466,809,692,507,310,000,000,000,000.00/yr
RYLD
Annual income on $10K today (after 15% tax)
$1,031.60/yr
After 10yr DRIP, annual income (after tax)
$2,199.25/yr
At 15% tax rate, ADYX beats the other by $125,466,809,692,507,310,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADYX + RYLD for your $10,000?

ADYX: 50%RYLD: 50%
100% RYLD50/50100% ADYX
Portfolio after 10yr
$8.123740858091492e+22M
Annual income
$73,804,005,701,474,890,000,000,000,000.00/yr
Blended yield
90.85%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADYX buys
0
RYLD buys
0
No recent congressional trades found for ADYX or RYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricADYXRYLD
Forward yield2000000.00%12.14%
Annual dividend / share$2.00$1.81
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%0%
Portfolio after 10y$1.6247481716182984e+23M$44.5K
Annual income after 10y$147,608,011,402,949,780,000,000,000,000.00$2,587.35
Total dividends collected$1.6146053563276882e+23M$18.8K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: ADYX vs RYLD ($10,000, DRIP)

YearADYX PortfolioADYX Income/yrRYLD PortfolioRYLD Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,914$1,213.65+$100.00MADYX
2$467,446,731,075$467,339,719,626.17$14,099$1,351.30+$467446.72MADYX
3$1,021,215,363,816,662$1,020,715,195,814,411.90$16,580$1,494.55+$1021215363.80MADYX
4$1,043,112,617,104,109,200$1,042,019,916,664,825,300.00$19,384$1,642.61+$1043112617104.09MADYX
5$498,482,143,759,731,400,000$497,366,013,259,430,040,000.00$22,535$1,794.70+$498482143759731.38MADYX
6$111,599,275,650,097,780,000,000$111,065,899,756,274,860,000,000.00$26,063$1,950.00+$111599275650097776.00MADYX
7$11,738,678,336,351,557,000,000,000$11,619,267,111,405,953,000,000,000.00$29,995$2,107.69+$11738678336351557632.00MADYX
8$583,674,362,697,175,100,000,000,000$571,113,976,877,278,900,000,000,000.00$34,361$2,266.99+$583674362697175072768.00MADYX
9$13,894,210,989,607,547,000,000,000,000$13,269,679,421,521,570,000,000,000,000.00$39,194$2,427.12+$1.3894210989607547e+22MADYX
10$162,474,817,161,829,840,000,000,000,000$147,608,011,402,949,780,000,000,000,000.00$44,525$2,587.35+$1.6247481716182984e+23MADYX

ADYX vs RYLD: Complete Analysis 2026

ADYXStock

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.

Full ADYX Calculator →

RYLDETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →
📬

Get this ADYX vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADYX vs SCHDADYX vs JEPIADYX vs OADYX vs KOADYX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.